Please login to the form below

Not currently logged in

S-A and Exelixis forge alliance

Sanofi-aventis(S-A) and biotech firm Exelixis collaborate on novel targeted oncology therapies

Sanofi-aventis(S-A) and Exelixis, a development stage biotech company, have joined forces to develop novel targeted oncology therapies. The two companies have entered into a global license agreement for XL147 and XL765 and an exclusive collaboration for the discovery of inhibitors of phosphoinositide-3 kinase (PI3K) for the management of solid malignancies.

Under the agreement, S-A will have an exclusive worldwide license to XL147, an oral PI3K inhibitor, and XL765, an oral dual inhibitor of PI3K and mTOR (mammalian target of rapamycin), both of which are in phase I clinical trials. The French company will have sole responsibility for all subsequent clinical, regulatory, manufacturing and commercial activities. Exelixis will take part in ongoing and potential future clinical trials.

S-A and Exelixis will combine research efforts to establish several preclinical programmes related to isoform-selective inhibitors of PI3K. Under the exclusive discovery collaboration, S-A will have sole responsibility for all subsequent clinical, regulatory, commercial and manufacturing activities of the products that result from the collaboration.

Under the terms of the agreements, S-A will pay Exelixis an upfront cash payment, as well as development and regulatory milestone payments that could reach over $1bn in aggregate for existing and future programmes. Exelixis will also receive royalties and commercial milestones on sales when products are commercialised. 

28th May 2009


Featured jobs

Subscribe to our email news alerts


Add my company
Grace Communications

Grace Communications is a creative agency specialising in healthcare communication and understanding people's personality types....

Latest intelligence

Australian Flu and the dilemma of naming diseases
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....